Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM8 | Q7Z2W7 | 11/20 | 0.49 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.43 |
| ▸ | TAS2R14 | Q9NYV8 | 3/20 | 0.40 |
| ▸ | PTGES | O14684 | 3/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.39 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1099996 | 0.90 | KEAP1 (0.37) | TRPM8MEN1KMT2AKEAP1NFE2L2 | |
| SCHEMBL1099360 | 0.89 | MCL1 (0.56) | TRPM8MCL1TAS2R14PTGESALOX5 | |
| SCHEMBL1099776 | 0.86 | TRPM8 (0.52) | TRPM8MCL1TAS2R14PTGESALOX5 | |
| SCHEMBL1100757 | 0.84 | TRPM8 (0.53) | TRPM8TAS2R14PTGESALOX5MEN1 | |
| SCHEMBL1099503 | 0.84 | TRPM8 (0.50) | TRPM8MCL1TAS2R14PTGESALOX5 | |
| SCHEMBL1098422 | 0.83 | TRPM8 (0.49) | TRPM8MCL1TAS2R14PTGESALOX5 | |
| SCHEMBL1099722 | 0.82 | TRPM8 (0.51) | TRPM8TAS2R14PTGESALOX5MEN1 | |
| SCHEMBL1100381 | 0.82 | PTGES (0.52) | TRPM8TAS2R14PTGESALOX5MEN1 | |
| SCHEMBL1099163 | 0.82 | ALOX5 (0.57) | TRPM8MCL1TAS2R14PTGESALOX5 | |
| SCHEMBL1098386 | 0.82 | TRPM8 (0.51) | TRPM8TAS2R14PTGESALOX5MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9434711-B2 | Sulfonamides as TRPM8 modulators | JANSSEN PHARMACEUTICA, N.V. (BE) | 2016-09-06 | — | — | US | disclosed |
| US-20140315899-A1 | SULFONAMIDES AS TRPM8 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-10-23 | — | — | US | disclosed |
| US-8809327-B2 | Sulfonamides as TRPM8 modulators | JANSSEN PHARMACEUTICA, NV (BE) | 2014-08-19 | — | — | US | disclosed |
| EP-2183239-B1 | SULFONAMIDES AS TRPM8 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2012-08-22 | — | — | EP | disclosed |
| US-20120190674-A1 | SULFONAMIDES AS TRPM8 MODULATORS | BRANUM SHAWN T (US) | 2012-07-26 | — | — | US | disclosed |
| US-8153682-B2 | Sulfonamides as TRPM8 modulators | JANSSEN PHARMACEUTICA, NV (BE) | 2012-04-10 | — | — | US | disclosed |
| US-20090264474-A1 | SULFONAMIDES AS TRPM8 MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120190674-A1 | SULFONAMIDES AS TRPM8 MODULATORS | TRPM8, TRPM5, TRPM2 | TRPM8 1/4885MCL1 3803/4885TAS2R14 182/4885 |
| US-20140315899-A1 | SULFONAMIDES AS TRPM8 MODULATORS | TRPM8, TRPM5, TRPM2 | TRPM8 1/4885MCL1 3803/4885TAS2R14 182/4885 |
| US-20090264474-A1 | SULFONAMIDES AS TRPM8 MODULATORS | TRPM8, TRPM5, TRPM2 | TRPM8 1/4885MCL1 3803/4885TAS2R14 182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.